Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 3
2011 3
2012 2
2013 4
2014 10
2015 11
2016 10
2017 9
2018 11
2019 13
2020 14
2021 18
2022 14
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, Naulaerts S, Borras DM, Kinget L, Fucíková J, Špíšek R, Jelínková LP, Kepp O, Kroemer G, Krysko DV, Coosemans A, Vaes RDW, De Ruysscher D, De Vleeschouwer S, Wauters E, Smits E, Tejpar S, Beuselinck B, Hatse S, Wildiers H, Clement PM, Vandenabeele P, Zitvogel L, Garg AD. Sprooten J, et al. Among authors: beuselinck b. Oncoimmunology. 2023 Jun 3;12(1):2219591. doi: 10.1080/2162402X.2023.2219591. eCollection 2023. Oncoimmunology. 2023. PMID: 37284695 Free PMC article. Review.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: beuselinck b. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK. Bakouny Z, et al. Among authors: beuselinck b. Eur Urol. 2023 Feb;83(2):145-151. doi: 10.1016/j.eururo.2022.10.004. Epub 2022 Oct 20. Eur Urol. 2023. PMID: 36272943
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC. Dudani S, et al. Among authors: beuselinck b. JAMA Netw Open. 2021 Jan 4;4(1):e2021869. doi: 10.1001/jamanetworkopen.2020.21869. JAMA Netw Open. 2021. PMID: 33475752 Free PMC article.
Three Years After CARMENA: What Have We Learned?
Roussel E, Beuselinck B, Albersen M. Roussel E, et al. Among authors: beuselinck b. Eur Urol. 2021 Oct;80(4):425-427. doi: 10.1016/j.eururo.2021.07.007. Epub 2021 Jul 27. Eur Urol. 2021. PMID: 34325948
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA, Meza L, Pal SK, Szabados B, Powles T, Beuselinck B, McKay RR, Lee JL, Ernst DS, Kapoor A, Yuasa T, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: beuselinck b. Eur Urol Oncol. 2023 Oct 30:S2588-9311(23)00217-1. doi: 10.1016/j.euo.2023.10.002. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37914579
Molecular subtypes and prognosis in RCC.
Beuselinck B, Fridman WH, Zucman-Rossi J. Beuselinck B, et al. Aging (Albany NY). 2015 Apr;7(4):219-20. doi: 10.18632/aging.100736. Aging (Albany NY). 2015. PMID: 25885644 Free PMC article. No abstract available.
Expanding the Role of Ultrasound for the Characterization of Renal Masses.
Roussel E, Campi R, Amparore D, Bertolo R, Carbonara U, Erdem S, Ingels A, Kara Ö, Marandino L, Marchioni M, Muselaers S, Pavan N, Pecoraro A, Beuselinck B, Pedrosa I, Fetzer D, Albersen M, On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group. Roussel E, et al. Among authors: beuselinck b. J Clin Med. 2022 Feb 19;11(4):1112. doi: 10.3390/jcm11041112. J Clin Med. 2022. PMID: 35207384 Free PMC article. Review.
110 results